Home / Health / AI Accelerates Rare Disease Drug Development, Experts Reveal
AI Accelerates Rare Disease Drug Development, Experts Reveal
21 Aug
Summary
- Experts discuss obstacles and solutions for rare disease clinical trials
- AI is being used to speed up rare disease drug development
- Cybersecurity challenges arise from digital transformation of clinical trials
In September 2025, clinical development and operations professionals will convene at the 3rd Annual Clinical Trials in Rare Diseases (CTRD) meeting in Princeton, New Jersey. The event will bring together experts from the pharmaceutical and biotech sectors to discuss the obstacles and solutions to clinical trial operational issues for rare diseases, as well as explore the evolving landscape of these trials with a focus on innovation, collaboration, and patient-centric approaches.
Concurrently, the 3rd Annual Clinical Data Management Innovation (CDMI) conference will explore ways to streamline data entry and collection, make better use of real-world evidence, and address the evolving regulatory environment around clinical data. A key highlight will be a talk by Bruce Bloom, CEO of Fortuity Pharma, who will showcase how artificial intelligence (AI) is accelerating rare disease drug development, including processes for pre-IND packages and working with the FDA.
Additionally, the CDMI conference will feature a keynote by Jeff Malavasi of Scholar Rock, who will address the growing cybersecurity challenges created by the digital transformation of clinical trials. Malavasi will provide a practical framework for adopting AI-driven security solutions to safeguard sensitive clinical data.
